Because no two people are alike, Antigenics Inc. believes that the best medicine consists of a unique and individualized approach for each patient. This progressive way of thinking has grown our company from just two people to more than 200 in a few short years and has positioned us firmly at the forefront of the fields of personalized medicines and revolutionary immunotherapies.
Antigenics has emerged as an industry leader based on our experience with preclinical and clinical research, proprietary technology platforms and strategic business expertise. Since inception, Antigenics has achieved several important milestones, including advancing six products in clinical studies, including pivotal trials; securing more than 80 U.S. patents to establish dominant intellectual property positions in our fields; developing five technology platforms; and maintaining a strong balance sheet. Promising findings from our clinical trials of our leading product - a personalized cancer vaccine - together with other development programs in cancers, infectious diseases and autoimmune disorders, all help to ensure our strength in the marketplace for years to come.
Antigenics attracts the industry's most talented professionals. As we continue to grow and prosper, so will our need for the best and brightest at our corporate headquarters in New York City, and at our research, development and manufacturing facilities in Woburn and Framingham, Massachusetts.
We are true pioneers in the biomedical field, yet we offer the career stability expected of a much larger corporation.